Yarrow Bioscience closed at $14.91 on Nov 4, down 18.84%, within 0.0% of its lowest close since Sep 11. Volume of 98.9K shares was 0.57× its 20-day average (below normal).
Split-adjusted performance: -20.4% over one month.
Short interest was 132.0K shares at the Oct 15 settlement, down 30.4% from the prior report (2.0% of float, 1.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| YARWYarrow Bioscience | $14.91 | −18.84% | — | — | — | — | $125.8M | |
| FHTXFoghorn Therapeutics | $2.10 | −1.41% | −55.1% | +112.7% | −44.7% | — | $124.7M | Compare |
| NKTXNkarta | $1.73 | +13.07% | −47.9% | — | — | — | $123.9M | Compare |
| NERVMinerva Neurosciences | $2.57 | +9.36% | −58.7% | — | — | — | $122.7M | Compare |
| DERMJourney Medical | $4.73 | +1.94% | −9.2% | +18.9% | −1.7% | — | $133.5M | Compare |
| SPRBSpruce Biosciences | $46.61 | +8.88% | −19.5% | — | — | — | $134.0M | Compare |
| PYXSPyxis Oncology | $1.66 | +1.22% | −27.8% | −100.0% | — | — | $138.5M | Compare |
| ANIXAnixa Biosciences | $3.28 | +7.37% | +7.2% | — | — | — | $114.0M | Compare |
| ORGOOrganogenesis Holdings | $0.8700 | +4.19% | −66.0% | −56.7% | −227.0% | — | $111.9M | Compare |
No recent articles focused on Yarrow Bioscience.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
